Goldman Sachs Call 200 CHKP 21.06.../ DE000GG7AGF6 /
| 2024-05-21 9:19:32 AM | Chg.0.000 | Bid2024-05-21 | Ask2024-05-21 | Underlying | Strike price | Expiration date | Option type |
|---|---|---|---|---|---|---|---|
| 0.001EUR | 0.00% | 0.001 Bid Size: 10,000 |
- Ask Size: - |
Check Point Software... | 200.00 USD | 2024-06-21 | Call |
GlobeNewswire
05-20
DEADLINE ALERT for HRT, CKPT, SOND, QDEL: Law Offices of Howard G. Smith Reminds Investors of Class ...
GlobeNewswire
05-20
CKPT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Checkpoint Therapeutics, Inc. ...
GlobeNewswire
05-20
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Checkp...
GlobeNewswire
05-20
GigaGen Doses First Patient in Phase 1 Trial of Anti-CTLA-4 Oncology Drug Candidate GIGA-564 in Adva...
GlobeNewswire
05-20
Perspective Therapeutics to Present at the Society of Nuclear Medicine and Molecular Imaging (SNMMI)...
GlobeNewswire
05-18
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Checkpoint Therapeutics, Inc. Investors to Secure Co...
GlobeNewswire
05-17
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Hir...
GlobeNewswire
05-15
Molecular Templates, Inc. Reports First Quarter 2024 Financial Results and Corporate Update
GlobeNewswire
05-15
Fortress Biotech Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
GlobeNewswire
05-15
Kineta Reports First Quarter 2024 Financial Results and Provides Update on its Ongoing Phase 1/2 VIS...
GlobeNewswire
05-15
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Agains...
GlobeNewswire
05-15
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Checkpoin...
GlobeNewswire
05-15
Medigene Presents Preclinical Data on Optimal Affinity TCRs Targeting the Neoantigen Mutant KRAS
GlobeNewswire
05-15
PDS Biotech Provides Business Update and Reports First Quarter 2024 Financial Results
GlobeNewswire
05-15
ROSEN, NATIONAL TRIAL COUNSEL, Encourages Checkpoint Therapeutics, Inc. Investors to Secure Counsel ...
GlobeNewswire
05-14
NANOBIOTIX Announces US FDA Protocol Acceptance for New Randomized Phase 2 Study Evaluating NBTXR3 f...
GlobeNewswire
05-14
Shattuck Labs to Present Additional Data from the Phase 1B Dose Expansion Clinical Trial of SL-17215...
GlobeNewswire
05-14
BioAtla Reports First Quarter 2024 Financial Results and Highlights Recent Progress
GlobeNewswire
05-14
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. ...
GlobeNewswire
05-13
DEADLINE ALERT for AVXL, HRT, and CKPT: The Law Offices of Frank R. Cruz Reminds Investors of Class ...
GlobeNewswire
05-13
DEADLINE ALERT for HRT, CKPT, SOND, QDEL: Law Offices of Howard G. Smith Reminds Investors of Class ...
GlobeNewswire
05-13
CKPT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Checkpoint Therapeutics, Inc. ...
